Benefits of more aggressive VTE prophylaxis in hospitalized medical patients

Cleveland Clinic Journal of Medicine

Volumn 71, Issue 12, 2004, Pages 947-960

  Menajovsky, Leon Bernardo ^a   Spandorfer, John ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; SODIUM N [8( 2 HYDROXYBENZOYL) AMINO] CAPRYLATE HEPARIN; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT;

BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEMATOMA; HIGH RISK PATIENT; HOSPITAL COST; HOSPITALIZATION; HUMAN; INJECTION SITE REACTION; LUNG EMBOLISM; META ANALYSIS; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREDICTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SKIN BRUISING; SURGICAL RISK; SYMPTOMATOLOGY; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTICOAGULANTS; CHEMOPREVENTION; CLINICAL PROTOCOLS; EVIDENCE-BASED MEDICINE; GUIDELINES; HOSPITALIZATION; HUMANS; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 13844272700     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.71.12.947     Document Type: Review

References (53)

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. Chest 2004; 126:338S-400S.
2. Bick RL, Haas SK. International consensus recommendations. Summary statement and additional suggested guidelines. European Consensus Conference, November 1991. American College of Chest Physicians consensus statement of 1995. International Consensus Statement, 1997. Med Clin North Am 1990; 82:613-633.
3. Goldhaber SZ, Dunn K, MacDougall RC. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest 2000; 118:1680-1684.
4. Centers for Disease Control and Prevention/National Center for Health Care Statistics. National Hospital Discharge Survey, 1997. Centers for Disease Control. Available at: www.cdc.gov/nchs. Accessed January 6, 2003.
5. Heit JA, Melton LJ, 3rd, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001; 76:1102-1110.
6. Kim V, Spandorfer J. Epidemiology of venous thromboembolic disease. Emerg Med Clin North Am 2001; 19:839-859.
7. Alpert JS, Dalen JE. Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 1994; 36:417-422.
8. Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 2001; 161:1268-1279.
9. Anderson FA, Jr., Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152:1660-1664.
10. Second Thromboembolic Risk Factors (THRIFT II) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Phlebology 1998; 13:87-97.
11. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol 1997; 50:609-610.
12. Goldhaber SZ. Pulmonary embolism. N Engl J Med 1998; 339:93-104.
13. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159:445-453.
14. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7.
15. Mohr DN, Silverstein MD, Heit JA, Petterson TM, O'Fallon WM, Melton LJ. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clin Proc 2000; 75:1249-1256.
16. Tanios MA, Simon AR, Hassoun PM. Management of venous thromboembolic disease in the chronically critically ill patient. Clin Chest Med 2001; 22:105-122.
17. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386-1389.
18. Agnelli G, Taliani MR, Verso M. Building effective prophylaxis of deep vein thrombosis in the outpatient setting. Blood Coagul Fibrinolysis 1999; 10(suppl 2):S29-S35.
19. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26:115-117.
20. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96:561-565.
21. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10:448-450.
22. Cade JF, Andrews JT, Stubbs AE. Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Aust N Z J Med 1982; 12:501-504.
23. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16:159-164.
24. Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate S, et al. Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 1988; 39:505-513.
25. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis 1996; 26:127-139.
26. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis 1996; 26(suppl 2):49-56.
27. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 1996; 76:529-534.
28. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet 1996; 347:1357-1361.
29. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83:14-19.
30. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88:913-930.
31. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341:793-800.
32. Cohen AT, Zaw HM, Alikhan R. Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Semin Hematol 2001; 38(suppl 5):31-38.
33. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in medical patients with enoxaparin (MEDENOX) trial. Am J Cardiol 2000; 86(12 suppl 2):48-52.
34. Hull RD, Kakkar AK, Marder VJ, Pineo GF, Goldberg MM, Raskob GE. Oral-SNAC heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement (abstract 558). Blood 2002; 100:148a-149a.
35. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboebolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003; 145:614-621.
36. Cohen AT, Alikhan R. Prophylaxis of venous thromboembolism in medical patients. Curr Opin Pulm Med 2001; 7:332-337.
37. Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110:874-879.
38. Cohen AT, Gallus AS, Lassen MR, et al. Fondaparinux vs placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS). Program and abstracts of the XIX Congress of the International Society on Thrombosis and Haemostatis; Birmingham, UK, July 12-13, 2003. P2406.
39. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000; 160:2208-2215.
40. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003; 163:901-908.
41. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 2001; 120:1964-1971.
42. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386-1389.
43. Eikelboom JW, Quinlan DJ, Douketis J. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trials. Lancet 2001; 358:9-15.
44. Freedman KB, Brookenthal KR, Fitzgerald RH, Jr., Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 2000; 82-A:929-938.
45. Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159:457-460.
46. Nuijten MJ, Berto P, Kosa J, Nadipelli V, Cimminiello C, Spreafico A. Cost-effectiveness of enoxaparin as thromboprophylaxis in acutely ill medical patients from the Italian NHS perspective. Recenti Prog Med 2002; 93:80-91.
47. Audet AM, Anderson FA, St John R. The prevention of venous thromboembolism: a statewide evaluation of practices in Massachusetts. Therapie 1998; 53:591-594.
48. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002; 137:648-655.
49. Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran, followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Heamost 2003; 1:2490-2496.
50. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of Ximelagatran woth warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349:1703-1712.
51. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360:1441-1447.
52. Colwell CW, Berkowitz SD, Davidson BL, et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and enoxaparin to prevent venous thromboembolism (VTE) after total hip arthroplasty (THA) (abstract 2952). Blood 2001; 98:706a.
53. PRNewswire-FirstCall. Emisphere Technologies reports results from phase III oral heparin PROTECT trial. Emisphere Technologies. Available at: http://www.emisphere.com/new/home.htm. Accessed June 4, 2002.